



EXAMINER: Initial if citation ensidered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Λ

SEP 2 4 2001 SE

THAUENARY.					S	heet 2 of	<u>5</u>	
Form PTO-1449 U.S	. Departmei Patent	Atty. Doc 59597-D/J	ket No. PW/AJM/CMR		Serial No. 19/766,344			
INFORMAT (Use :	TION DISC	Applicants Neil T. Parkin and Rainer A. Ziermann						
		Filing Da January	te 19, 2001	Group A	Group Art Unit			
		U.S. PATI	ENT DOCUMENTS					
Examiner Document Initial	Number	Date	Name	Class	Subclass	Filing Date if Appropriate		
	+++			 		 		
				`				
		FOREIGN PA	ATENT DOCUMENT	rs		<u> </u>		
Document	Number	Date_	Country	Class	Subclass	-Translation		
	- · · ·					Yes	No	
	 - - -	-						
						-		
		<u> </u>		-				
ОТИ	ER DOCU	MENTS (Includin	g Author, Title, Date,	Portinent l	Pages Eta)		<u>_</u>	
Protease Virions 36:982-9	Inhib From Cl 88 (Exl	itors Irrenronically	2) "Human Imm eversibly Blo Infected Ce	ock Int lls" <u>An</u>	fectivity it Microb	of P Agen	urified ts Chem	
Sustaine	d Antir	etroviral	al., (1995) Efficacy of <i>F</i> xhibit 9) ;					
Glycopro Activity	tein c of th levant	on the An e Inhibito HIV Protea	l., (1997) " ti-Human Im or CGP 61775 se Inhibitors	munodet	ficiency omparativ	Virus e Stu	(HIV) dy with	
Human	Plasma ficiend	Proteins	al., (1995) s and Imp Therapy", <u>J</u>	licatio	ons for	Ant	i-Humar	
1 1	of Dr	ug Resista	et al., (19)	•				
EXAMINER Shame	1	DATE CONSIDERE	1/11/2					
*EXAMINER: Initial if citation conformance and not considered.					: Draw line throu	gh citation	if not in	



Sheet <u>3</u> of <u>6</u>

Form PTO-	1449	U.S. Department of Commerce Patent and Trademark Office							Atty. Dock 59597-D/3	et No. JPW/AJM/CMR	Serial No. 09/766,344		
	I	NFO					OSURE CITAT: s if necessary)	ION	Applican Neil T. 1	ts Parkin and Ra	iner A.	Ziermann	
								Filing Da January	te 7 19, 2001	Group A	Art Unit		
							U.S. PAT	ENT DOCUMENTS					
Examiner Initial		De	cume	nt N	umber		Date	Name	Class	Subclass	Filing Da		
ļ			$\vdash \vdash$	_	_	+							
		-	<u> </u>			+-					 		
		╁		\dashv	-	+-					 		
		<u> </u>					FOREIGN P.	ATENT DOCUMEN	NTS	<u> </u>			
		Doc	umer	nt N	lumbe	er	Date	Country	Class	Subclass	Translation		
								-			Yes	No	
		_		_	\perp	\perp							
		<u> </u>	-	_									
	į	ļ		-			L						
								ng Author, Title, Dat					
St	Pr	ot	eas	е	wit	h a	a Substrat	`Structure c ce-Based Inh xhibit 13);					
	Ηu		n I	mm	uno	def	iciency V	"Quantitat irus Type 1 <u>S</u> 90: 25-29	in the	Blood of			
	or In	Ar mu	mpre nod	en ef	avi:	r w enc	ith Zidovu	(1999) "Trodine and La Infection" <u>G</u>	mivudin	e in Adult	s wit	h Human	
	Mu Vi	ta ru	tio s T	ns yp	in	th Is	e Reverse	"Natural Oo Transcripta <u>Aids Res Hu</u>	se of F	luman Immu	ınodef	iciency	
SH	Im in	mui V:	irus	ef s	ici	enc n Pa	y Virus: M atients Un	95) "pol G Mutations As dergoing No	sociate	d with Dru	ıg Res	istance	
EXAMINER	She		//-	1/			DATE CONSIDERE	D 1/11/2					
								conformance with MPEP nunication to applicant.	609: Draw line	through citation if n	ot in		

Λ

							40			S	heet 4 of 6		
Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office									Atty. Docket No. Serial No. 09/766, 59597-D/JPW/AJM/CMR				
101P	E SO						OSURE CITATI	ON	Applicants Neil T. Pa	rkin and Rainer	A. Zierma	ınn	
(Use several sheets if necessary)									Filing Date January 1	19, 2001	Group Art Unit		
\	ي ج						U.S. PAT	ENT DOCUMENTS					
Examinar & T	RADENME	Docu	iment l	Nu	mber		Date	Name	Class	Subclass	Filing Dat		
			+	╀		+			<u> </u>		_	<u>-</u>	
			+	╀	+	-						-V	
			+	╁	+	╁							
				_			FOREIGN P	ATENT DOCUMENT	`S			<u> </u>	
		Docu	ment	Νι	ımbe	r .	Date	Country		Subclass	Translation		
											Yes	No	
				L	\perp								
				1	\perp				- In the second		1		
-		<u> </u>	1	1	1	1						,	
				1	ED D		AMENITO (I I. II.	 ng Author, Title, Date,	D 42 4 F	<u> </u>	1	. '	
SAF	Is Cu Ne Su Vi 18	olatrer il scer rus 0: 8	T. Otik Typ 865	Cl oi oe -8	re in: Par lit 1	Creica kir y (H	oss-resist l Developm , et al. Associated IVA1) Trip xhibit 19		Antire 13: 6 Phenoty re of F ion The	etroviral 61-667 (Ex ppic chan Human Immu erapy", J_	Compo xhibit ges inodef	unds in 18); in Drugiciency	
	Ch Is In	arad olat hibi	cte: es to:	ri w rs	zat ith	tio Re H	n of Huma educed Sen	t al., (199 n Immunodefi sitivity to F ctyl Protease	ciency Hydroxy	Virus Ty ethylamin	pe 1 o Sulf	(HIV-1) Tonamide	
	Is Ne (E	olat lfir xhib	cten ced navi	ri ir 2	zat fro :", 21)	io m <u>An</u>	n of Humar Patients timicrobia	., (1998) n Immunodefic Treated wi al Agents and	ciency th the Chemo	Virus Type Proteas	pe 1 V se In 42: 26	hibitor 37-2644	
SH	Pe Dr	tit ug J	SC Disc	, cc	et ov]	a: Des	1. (1993) 1:69-83	"The Specifi (Exhibit 22)	city o	of the HI	V-1 Pi	rotease'	
EXAMINE		m	1/1	h			DATE CONSID	DERED ///2					
	R: Initial i	f citatio						s in conformance with M communication to applic		aw line through cita	ation if not	in	

Sheet 5 of 6 Atty. Docket No. Serial No. Form PTO-1449 U.S. Department of Commerce 59597-D/JPW/AJM/CMR |09/766,344 Patent and Trademark Office FORMATION DISCLOSURE CITATION Neil T. Parkin and Rainer A. Ziermann (Use several sheets if necessary) Filing Date Group Art Unit January 19, 2001 **U.S. PATENT DOCUMENTS** Date Class xaminer Document Number Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Subclass Translation Class Yes OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Roberts NA, et al. (1990) "Rational Design of Peptide-Based HIV 8/2 Proteinase" Science 248:358-361 (Exhibit 23); Roberts, N. A., (1995) "Drug-resistance patterns of saquinavir and other HIV proteinase inh/ibitors", AIDS.9 (supp 2) (Exhibit 24); Brian M. Sadler, et al., (1999) "Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults", Antimicrobial Agents and Chemotherapy, 43: 1686-1692 (Exhibit 25); Sarkar G. and Sommer SS., (1990) "The "Megaprimer" Method of Site-Directed Mutagenesis", BioTech 8(4):404-407 (Exhibit 26); (1996) "A al., Smidt, et Mutation Immunodeficiency Virus Type 1 Protease at Position 88, Located Confers Resistance Active Site, Hydroxyethylurea Inhibitor SC-55389A", Antimicrobial Agents and Chemotherapy, 41: 515-522 (Exhibit 27); M. H. St. Clair, et al., (1996) "In Vitro Antiviral Activity of 84 141W94 (VX-478) in Combination with Other Antiretroviral Agents", Antiviral Research 29: 53-56 (Exhibit 28); DATE CONSIDERED EXAMINER

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant

Form PTO-1449 U.S. Department of Commerce										et No.	Serial No.				
Patent and Trademark Office										59597-D/JPW/AJM/CMR 09/766,344					
SEP 2 4 2001 55									Applicants Neil T. Parkin and Rainer A. Ziermann						
									Filing Date January 1		Group Ai	 -			
E.		/					U.S. PAT	ENT DOCUMENTS	<u>. I</u>		1	1			
Examiner Initial	ANA	Do	ocum	ent N	umber		Date	Name	Class	Subclass	1 9	Filing Date if Appropriate			
		<u> </u>													
		igspace	Щ	\Box	\perp	↓_			<u> </u>	<u> </u>	<u> </u>				
<u> </u>		1	Ш							<u> </u>					
·	 T							ATENT DOCUMENT	F		1				
		Doc	ume	ent N	umbe	r	Date	Country	Class	Subclass	Translation				
	_		1		-	Т.				1	Yes	No			
			\vdash			 		-							
					1	\vdash									
<u>.</u>	L	<u> </u>		THE	P DO		 	l 1g Author, Title, Date	Partinant	Pages Etc.)	<u> </u>				
SF	Pr 2 ⁿ	ec d I	ede Int	ed ern	by a	a I	ransient al Worksho	"Zidovudine/ Period of Zi op on HIV Dr (Exhibit 29	idovudi ug Res	ne Hypers	ensit	ivity",			
	HI	t V	fro	m p	pati	ent	s on ZDV/	: "Genotypic 3TC/amprenavi ct No. 32312	ir comb	ination t					
	Conf AIDS 12:583 (Abstract No. 32312) (Exhibit 30); Simon P. Tucker, et al., (1998) "Estimate of the Frequency of Human Immunodeficiency Virus Type 1 Protease Inhibitor Resistance Within Unselected Virus Populations In Vitro", Antimicrobial Agents and Chemotherapy, 42: 478-480 (Exhibit 31);														
	Young, B. et al., (1998) "Resistance mutations in protease and reverse transcriptase genes of human immunodeficiency virus type 1 isolates from patients with combination antiretroviral therapy failure. J. Infectious Disease, 178: 1497-1501 (Exhibit 32); and														
SHE	Pr	ote	eas	se,	N-	-88	S, that	(in press Ma Causes In 4: 4414-4419	Vitro	Hyperser					
EXAMINER	1		<i>[[</i>]-	n le			DATE CONSIDERE	D 1/4/2							
			tatio	ncon	sidere			on is in conformance wit		: Draw line throu	gh citation	if not in			

•